Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 13/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990361 | 0.87 | LMNA (0.50) | NPC1RAB9ALMNAGRM5L3MBTL1 | |
| SCHEMBL990881 | 0.87 | LMNA (0.50) | NPC1RAB9ALMNAGRM5L3MBTL1 | |
| SCHEMBL990087 | 0.86 | LMNA (0.50) | NPC1RAB9ALMNAGRM5L3MBTL1 | |
| SCHEMBL3379028 | 0.86 | GRM5 (0.46) | GRM5 | |
| SCHEMBL990822 | 0.85 | NPC1 (0.48) | NPC1RAB9ALMNAGRM5L3MBTL1 | |
| SCHEMBL990869 | 0.83 | GRM5 (0.48) | NPC1RAB9AGRM5L3MBTL1 | |
| SCHEMBL1907158 | 0.83 | GRM5 (0.46) | NPC1RAB9ALMNAGRM5L3MBTL1 | |
| SCHEMBL1907156 | 0.83 | GRM5 (0.46) | NPC1RAB9ALMNAGRM5L3MBTL1 | |
| SCHEMBL2815651 | 0.83 | GRM5 (0.46) | NPC1RAB9ALMNAGRM5L3MBTL1 | |
| SCHEMBL989512 | 0.83 | GRM5 (0.45) | NPC1RAB9AGRM5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137206-A1 | PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| EP-2320892-A2 | COMBINATION PRODUCTS | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |